Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma

被引:0
|
作者
Bekkenk, MW
Postma, TJ
Meijer, CJLM
Willemze, R
机构
[1] Leiden Univ, Med Ctr, Dept Dermatol, NL-2333 ZA Leiden, Netherlands
[2] Free Univ Amsterdam Hosp, Dept Dermatol, NL-1081 HV Amsterdam, Netherlands
[3] Free Univ Amsterdam Hosp, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[4] Free Univ Amsterdam Hosp, Dept Neurol, NL-1081 HV Amsterdam, Netherlands
关键词
cutaneous B-cell lymphoma; central nervous system involvement; incidence; prognosis;
D O I
10.1002/1097-0142(20000815)89:4<913::AID-CNCR26>3.0.CO;2-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND, Primary cutaneous B-cell lymphoma (CBCL) constitutes approximate to 20% of all primary cutaneous lymphomas. Apart from primary cutaneous large B-cell lymphoma presenting on the legs (PCLBCL-leg), primary CBCLs run an indolent clinical course, rarely disseminate to extracutaneous sites, and have an excellent prognosis. Because of recent observations in two patients who developed central nervous system (CNS) involvement, follow-up data of all primary CBCL patients registered at the Dutch Cutaneous Lymphoma Group between 1985 and 1998 were investigated for evidence of CNS involvement. METHODS, Follow-up data from 160 primary CBCLs were evaluated. This group included 122 primary cutaneous follicle center cell lymphomas (PCFCCLs), 16 primary cutaneous immunocytomas or marginal zone B-celI lymphomas, and 22 PCLBCL-leg. RESULTS, Of all 160 patients with primary CBCLs, 11 died of lymphoma, including 4 of 122 patients (3%) with PCFCCL and 7 of 22 patients (32%) with PCLBCL-leg. Four of these 11 patients, including 3 with PCFCCL and 1 with PCLBCL-leg, had developed CNS involvement 3-93 months (median, 30 months) after diagnosis. AU patients died 1-9 months (median, 7 months) after the development of CNS involvement In the group of 122 patients with PCFCCL, CNS involvement occurred in 3 of 7 patients (43%) who developed extracutaneous disease and accounted for 3 of 4 lymphoma-related deaths (75%). CONCLUSIONS. The results of this study indicate that approximately 2% of all primary CBCLs may develop CNS involvement. Whereas, in rare PCFCCL patients, developing extracutaneous disease CNS involvement was an important cause of death, patients with PCLBCL-leg and secondary CBCL died more frequently due to involvement of non-CNS organ systems. (C) 2000 American Cancer Society.
引用
收藏
页码:913 / 919
页数:7
相关论文
共 50 条
  • [41] Primary Diffuse Large B-cell Lymphoma of the Central Nervous System: Unmet Medical Need
    Asioli, Sofia
    Agostinelli, Claudio
    Morandi, Luca
    Zoli, Matteo
    Mazzatenta, Diego
    Iommi, Marica
    Righi, Simona
    Sabattini, Elena
    Zinzani, Pier Luigi
    Broccoli, Alessandro
    Bagnato, Ginmarco
    Cirillo, Luigi
    Tonon, Caterina
    Lodi, Raffaele
    Giannini, Caterina
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1187 - 1188
  • [42] Myc Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
    Gill, K.
    Hoehn, D.
    Alobeid, B.
    Bhagat, G.
    LABORATORY INVESTIGATION, 2014, 94 : 348A - 348A
  • [43] Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
    Monabati, Ahmad
    Nematollahi, Pardis
    Dehghanian, Amirreza
    Safaei, Akbar
    Sadeghipour, Alireza
    Movahedinia, Sajjadeh
    Mokhtari, Maral
    BASIC AND CLINICAL NEUROSCIENCE, 2020, 11 (04) : 491 - 498
  • [44] Management of Primary Diffuse Large B-cell Lymphoma of The Central Nervous System: Clinical Study
    Basmaci, Mehmet
    Hasturk, Askin Esen
    Ayata, Tulu
    JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, 2013, 30 (02): : 469 - 476
  • [45] Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma
    Fox, Christopher P.
    Phillips, Elizabeth H.
    Smith, Jeffery
    Linton, Kim
    Gallop-Evans, Eve
    Hemmaway, Claire
    Auer, Dorothee P.
    Fuller, Charlotte
    Davies, Andrew J.
    McKay, Pamela
    Cwynarski, Kate
    Jones, Gail
    Pratt, Guy
    Stern, Simon
    Lambert, Jonathan
    Parry-Jones, Nilima
    McKay, Pam
    Whiteway, Alastair
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (03) : 348 - 363
  • [46] MATRIX REGIMEN FOR NEWLY DIAGNOSED PRIMARY DIFFUSE B-CELL LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM
    Green, Richard
    Guzman-Marin, Ruben
    Lam, Keng
    Thornton, Colleen
    NEURO-ONCOLOGY, 2021, 23 : 73 - 73
  • [47] Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers
    Loser, Valentin
    Segot, Amandine
    de Leval, Laurence
    Bisig, Bettina
    Brouland, Jean-Philippe
    Hewer, Ekkehard
    Barcena, Carmen
    Hottinger, Andreas F.
    Pot, Caroline
    BMC NEUROLOGY, 2024, 24 (01)
  • [48] Primary central nervous system lymphoma B-cell receptors recognize specific antigens in the brain
    Spies, E.
    Mueller, F.
    Illerhaus, G.
    Glatzel, M.
    Trepel, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 73 - 73
  • [49] Diagnosis of primary central nervous system B-cell lymphoma despite prolonged cortisone medication
    Buss, A
    Assmus, A
    Weidemann, J
    Sellhaus, B
    Lorenzen, I
    Block, F
    NERVENARZT, 2004, 75 (12): : 1217 - 1221
  • [50] Lymphatic vessel involvement in primary cutaneous B-cell lymphoma: A common finding?
    Bertlich, Ines
    Hartmann, Julia
    Hartschuh, Wolfgang
    Enk, Alexander
    Toberer, Ferdinand
    JOURNAL OF CUTANEOUS PATHOLOGY, 2023, 50 (08) : 748 - 753